Use of behavioural and long-term potentiation models in the development of memory-improving drugs

Bibliography

• Lee J, Monette J, Sourial N, et al. The use of a cholinesterase inhibitor review committee in long-term care. J Am Med Dir Assoc 2007;8:243-7
   PubMed Web of Science ®Google Scholar
• Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci 2006;31:369-76
   PubMed Web of Science ®Google Scholar
• Raschetti R, Albanese E, Vanacore N, et al. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med 2007;4:e338
   PubMed Web of Science ®Google Scholar
• Small DH. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors? Expert Opin Emerging Drugs 2005;10:817-25
   PubMedGoogle Scholar
• Bolognesi ML, Minarini A, Tumiatti V, et al. Progress in acetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin Ther Patents 2006;16:811-23
   Web of Science ®Google Scholar
• Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol 2006;16:710-5
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Bevilaqua LR, Rossato JI, et al. Different molecular cascades in different sites of the brain control memory consolidation. Trends Neurosci 2006;29:496-505
   PubMed Web of Science ®Google Scholar
• Lynch G, Rex CS, Gall CM. LTP consolidation: substrates, explanatory power, and functional significance. Neuropharmacology 2007;52:12-23
   PubMed Web of Science ®Google Scholar
• Hebb DO. The organization of behavior: a neuropsychological theory. New York: Wiley; 1949
   Google Scholar
• Bliss TV, Gardner-Medwin AR. Long-lasting potentiation of synaptic transmission in the dentate area of the unanaestetized rabbit following stimulation of the perforant path. J Physiol 1973;232:357-74
   PubMed Web of Science ®Google Scholar
• Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973;232:331-56
   PubMed Web of Science ®Google Scholar
• Bliss TVP, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31-9
   PubMed Web of Science ®Google Scholar
• Raymond CR. LTP forms 1, 2 and 3: different mechanisms for the “long” in long-term potentiation. Trends Neurosci 2007;30:167-75
   PubMed Web of Science ®Google Scholar
• Nicoll RA, Schmitz D. Synaptic plasticity at hippocampal mossy fibre synapses. Nat Rev Neurosci 2005;6:863-76
   PubMed Web of Science ®Google Scholar
• Artola A, Singer W. Long-term depression of excitatory synaptic transmission and its relationship to long-term potentiation. Trends Neurosci 1993;16:480-7
   PubMed Web of Science ®Google Scholar
• Massey PV, Bashir ZI. Long-term depression: multiple forms and implications for brain function. Trends Neurosci 2007;30:176-84
   PubMed Web of Science ®Google Scholar
• Kullmann DM, Lamsa KP. Long-term synaptic plasticity in hippocampal interneurons. Nat Rev Neurosci 2007;8:687-99
   PubMed Web of Science ®Google Scholar
• Abraham WC. How long will long-term potentiation last? Philos Trans R Soc Lond B Biol Sci 2003;358:735-44
   PubMed Web of Science ®Google Scholar
• Jeffery KJ, Abraham WC, Dragunow M, et al. Induction of Fos-like immunoreactivity and the maintenance of long-term potentiation in the dentate gyrus of unanesthetized rats. Mol Brain Res 1990;8:267-74
   PubMedGoogle Scholar
• Krug M, Lössner B, Ott T. Anisomycin blocks the late phase of long-term potentiation in the dentate gyrus of freely moving rats. Brain Res Bull 1984;13:39-42
   PubMed Web of Science ®Google Scholar
• Frey U, Krug M, Reymann KG, et al. Anisomycin, an inhibitor of protein synthesis, blocks late phases of LTP phenomena in the hippocampal CA1 region in vitro. Brain Res 1988;452:57-65
   PubMed Web of Science ®Google Scholar
• Reymann KG, Frey U, Jork R, et al. Polymyxin B, an inhibitor of protein kinase C, prevents the maintenance of synaptic long-term potentiation in hippocampal CA1 neurons. Brain Res 1988;440:305-14
   PubMed Web of Science ®Google Scholar
• Malinow R, Madison DV, Tsien RW. Persistent protein kinase activity underlying long-term potentiation. Nature 1988;335:820-24
   PubMed Web of Science ®Google Scholar
• Reymann KG, Frey JU. The late maintenance of hippocampal LTP: requirements, phases, ‘synaptic tagging’, ‘late-associativity’ and implications. Neuropharmacology 2007;52:24-40
   PubMed Web of Science ®Google Scholar
• Lauri SE, Palmer M, Segerstrale M, et al. Presynaptic mechanisms involved in the expression of STP and LTP at CA1 synapses in the hippocampus. Neuropharmacology 2007;52:1-11
   PubMed Web of Science ®Google Scholar
• Lynch MA. Long-term potentiation and memory. Physiol Rev 2004;84:87-136
   PubMed Web of Science ®Google Scholar
• Chen L, Yamada K, Nabeshima T, et al. alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats. Neuropharmacology 2006;50:254-68
   PubMed Web of Science ®Google Scholar
• Gong B, Vitolo OV, Trinchese F, et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004;114:1624-34
   PubMed Web of Science ®Google Scholar
• Vitolo OV, Sant'Angelo A, Costanzo V, et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci USA 2002;99:13217-21
   PubMed Web of Science ®Google Scholar
• Ito T, Miura Y, Kadokawa T. Effects of physostigmine and scopolamine on long-term potentiation of hippocampal population spikes in rats. Can J Physiol Pharmacol 1988;66:1010-6
   PubMed Web of Science ®Google Scholar
• Barnes CA, Meltzer J, Houston F, et al. Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience 2000;99:17-23
   PubMed Web of Science ®Google Scholar
• Shinoe T, Matsui M, Taketo MM, et al. Modulation of synaptic plasticity by physiological activation of M1 muscarinic acetylcholine receptors in the mouse hippocampus. J Neurosci 2005;25:11194-200
   PubMed Web of Science ®Google Scholar
• Anagnostaras SG, Murphy GG, Hamilton SE, et al. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 2003;6:51-8
   PubMed Web of Science ®Google Scholar
• Seeger T, Fedorova I, Zheng F, et al. M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci 2004;24:10117-27
   PubMed Web of Science ®Google Scholar
• Iga Y, Arisawa H, Ise M, et al. Modulation of rhythmical slow activity, long-term potentiation and memory by muscarinic receptor agonists. Eur J Pharmacol 1996;308:13-9
   PubMed Web of Science ®Google Scholar
• Biton B, Bergis OE, Galli F, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: 1; binding and functional profile. Neuropsychopharmacology 2007;32:1-16
   PubMed Web of Science ®Google Scholar
• Lagostena L, Trocme-Thibierge C, Morain P, et al. The partial alpha7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 2008;54:676-85
   PubMed Web of Science ®Google Scholar
• Christian EP, Smith JS, Doherty JJ, et al. AZD0328: Dose-dependent normalization of hippocampal long term potentiation induction deficit in the fimbria/fornix lesioned rat in vivo. Soc Neurosci Meeting 2007;No. 906.9
   Google Scholar
• Frankiewicz T, Potier B, Bashir ZI, et al. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br J Pharmacol 1996;117:689-897
   PubMed Web of Science ®Google Scholar
• Frankiewicz T, Parsons CG. Memantine restores long term potentiation impaired by tonic N-methyl-D-aspartate (NMDA) receptor activation following reduction of Mg2+in hippocampal slices. Neuropharmacology 1999;38:1253-9
   PubMed Web of Science ®Google Scholar
• Zajaczkowski W, Frankiewicz T, Parsons CG, et al. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997;36:961-71
   PubMed Web of Science ®Google Scholar
• Drever BD, Anderson WG, Johnson H, et al. Memantine acts as a cholinergic stimulant in the mouse hippocampus. J Alzheimers Dis 2007;12:319-33
   PubMed Web of Science ®Google Scholar
• Barnes CA, Danysz W, Parsons CG. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci 1996;8:565-71
   PubMed Web of Science ®Google Scholar
• Misztal M, Frankiewicz T, Parsons CG, et al. Learning deficits induced by chronic intracerebroventricular infusion of quinolinic acid – protection by MK-801 and memantine. Eur J Pharmacol 1996;296:1-8
   PubMed Web of Science ®Google Scholar
• Ito I, Tanabe S, Kohda A, et al. Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. J Physiol 1990;424:533-43
   PubMed Web of Science ®Google Scholar
• Arai A, Lynch G. Factors regulating the magnitude of long-term potentiation induced by theta pattern stimulation. Brain Res 1992;598:173-84
   PubMed Web of Science ®Google Scholar
• Arai AC, Xia YF, Suzuki E. Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience 2004;123:1011-24
   PubMed Web of Science ®Google Scholar
• Martins TJ, Mumby MC, Beavo JA. Purification and characterization of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase from bovine tissues. J Biol Chem 1982;257:1973-79
   PubMed Web of Science ®Google Scholar
• Boess FG, Hendrix M, Van der Staay FJ, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004;47:1081-92
   PubMed Web of Science ®Google Scholar
• Barad M, Bourtchouladze R, Winder DG, et al. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc Natl Acad Sci USA 1998;95:15020-5
   PubMed Web of Science ®Google Scholar
• Ahmed T, Frey JU. Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro. Neuroscience 2003;117:627-38
   PubMed Web of Science ®Google Scholar
• Ahmed T, Frey S, Frey JU. Regulation of the phosphodiesterase PDE4B3-isotype during long-term potentiation in the area dentata in vivo. Neuroscience 2004;124:857-67
   PubMed Web of Science ®Google Scholar
• Otmakhov N, Khibnik L, Otmakhova N, et al. Forskolin-induced LTP in the CA1 hippocampal region is NMDA receptor dependent. J Neurophysiol 2004;91:1955-62
   PubMed Web of Science ®Google Scholar
• Trinchese F, Liu S, Battaglia F, et al. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004;55:801-14
   PubMed Web of Science ®Google Scholar
• Barco A. The Rubinstein-Taybi syndrome: modeling mental impairment in the mouse. Genes Brain Behav 2007;6(Suppl 1):32-9
   PubMed Web of Science ®Google Scholar
• Alarcon JM, Malleret G, Touzani K, et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004;42:947-59
   PubMed Web of Science ®Google Scholar
• Kuenzi F, Rosahl TW, Morton RA, et al. Hippocampal synaptic plasticity in mice carrying the rd mutation in the gene encoding cGMP phosphodiesterase type 6 (PDE6). Brain Research 2003;967:144-51
   PubMed Web of Science ®Google Scholar
• Monfort P, Munoz MD, Kosenko E, et al. Long-term potentiation in hippocampus involves sequential activation of soluble guanylate cyclase, cGMP-dependent protein kinase, and cGMP-degrading phosphodiesterase. J Neurosci 2002;22:10116-22
   PubMed Web of Science ®Google Scholar
• Makhinson M, Opazo P, Carlisle HJ, et al. A novel role for cyclic guanosine 3′,5′monophosphate signaling in synaptic plasticity: a selective suppressor of protein kinase A-dependent forms of long-term potentiation. Neuroscience 2006;140:415-31
   PubMed Web of Science ®Google Scholar
• Uthayathas S, Parameshwarani K, Karuppagounder SS, et al. Phosphodiesterase 5 inhibition enhances hippocampal long term potentiation in mice. Abstracts of the Society for Neuroscience meeting 2007;936.14
   Google Scholar
• Sarter M. Preclinical research into cognition enhancers. Trends Pharmacol Sci 2006;27:602-808
   PubMed Web of Science ®Google Scholar
• Clayton NS, Bussey TJ, Dickinson A. Can animals recall the past and plan for the future? Nat Rev Neurosci 2003;4:685-91
   PubMed Web of Science ®Google Scholar
• Weed MR, Taffe MA, Polis I, et al. Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance. 1999;8:185-201
   Google Scholar
• Chudasama Y, Robbins TW. Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans. Biol Psychol 2006;73:19-38
   PubMed Web of Science ®Google Scholar
• Yuede CM, Dong H, Csernansky JG. Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol 2007;18:347-63
   PubMed Web of Science ®Google Scholar
• Sarter M, Hagan JJ, Dudchenko P. Behavioral screening for cognition enhancers: from indiscriminate to valid testing part II. Psychopharmacology 1992;107:461-73
   PubMed Web of Science ®Google Scholar
• Blokland A, Schreiber R, Prickaerts J. Improving memory: a role for phosphodiesterases. Curr Pharm Des 2006;12:2511-23
   PubMed Web of Science ®Google Scholar
• Izquierdo I, Barros DM, Mello e Souza T, et al. Mechanisms for memory types differ. Nature 1998;393:635-36
   PubMed Web of Science ®Google Scholar
• Prickaerts J, Sik A, van Staveren WC, et al. Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 2004;45:915-28
   PubMed Web of Science ®Google Scholar
• Prickaerts J, Sik A, Van Der Staay FJ, et al. Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. Psychopharmacology 2005;177:381-90
   PubMed Web of Science ®Google Scholar
• Rutten K, Prickaerts J, Hendrix M, et al. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: Studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007;558:107-12
   PubMed Web of Science ®Google Scholar
• Bernabeu R, Schroder N, Quevedo.J, et al. Further evidence for the involvement of a hippocampal cGMP/cGMP-dependent protein kinase cascade in memory consolidation. Neuroreport 1997;8:2221-4
   PubMed Web of Science ®Google Scholar
• Sarter M. Measurement of cognitive abilities in senescent animals. Int J Neurosci 1987;32:765-74
   PubMed Web of Science ®Google Scholar
• Sarter M. Taking stock of cognitive enhaners. Trends Pharmacol Sci 1991;12:456-60
   PubMed Web of Science ®Google Scholar
• Steckler T, Muir J. Measurement of cognitive function: relating rodent performance with human minds. Cogn Brain Res 1996;3:299-308
   PubMedGoogle Scholar
• Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialogues Clin Neurosci 2006;8:109-13
   PubMedGoogle Scholar
• Hunter BE, de Fiebre CM, Papke RL, et al. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci Lett 1994;168:130-4
   PubMed Web of Science ®Google Scholar
• Van der Staay FJ, Hinz VC, Schmidt BH. Effects of metrifonate, its transformation product dichlorvos, and other organophosphorus and reference cholinesterase inhibitors on Morris water escape behavior in young-adult rats. J Pharmacol Exp Ther 1996;278:697-708
   PubMed Web of Science ®Google Scholar
• Bartus RT. Physostigmine and recent memory: effects in young and aged nonhuman primates. Science 1979;206:1087-9
   PubMed Web of Science ®Google Scholar
• Bartus RT, Johnson HR. Short-term memory in the rhesus monkey: disruption from the anti-cholinergic scopolamine. Pharmacol Biochem Behav 1976;5:39-46
   PubMed Web of Science ®Google Scholar
• Aigner TG, Mishkin M. The effects of physostigmine and scopolamine on recognition memory in monkeys. Behav Neural Biol 1986;45:81-7
   PubMedGoogle Scholar
• Stemmelin J, Cassel JC, Will B, et al. Sensitivity to cholinergic drug treatments of aged rats with variable degrees of spatial memory impairment. Behav Brain Res 1999;98:53-66
   PubMed Web of Science ®Google Scholar
• Dunnett SB, Evenden JL, Iversen SD. Delay-dependent short-term memory deficits in aged rats. Psychopharmacology 1988;96:174-80
   PubMed Web of Science ®Google Scholar
• Dong H, Csernansky CA, Martin MV, et al. Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology 2005;181:145-52
   PubMed Web of Science ®Google Scholar
• Cutuli D, Foti F, Mandolesi L, et al. Cognitive performance of healthy young rats following chronic donepezil administration. Psychopharmacology 2008;197:661-73
   PubMed Web of Science ®Google Scholar
• Sambeth A, Riedel W, Smits L, et al. Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? Eur J Pharmacol 2007;572:151-9
   PubMed Web of Science ®Google Scholar
• Van der Staay FJ, Bouger PC. Effects of the cholinesterase inhibitors donepezil and metrifonate on scopolamine-induced impairments in the spatial cone field orientation task in rats. Behav Brain Res 2005;156:1-10
   PubMed Web of Science ®Google Scholar
• Rupniak NM, Tye SJ, Field MJ. Enhanced performance of spatial and visual recognition memory tasks by the selective acetylcholinesterase inhibitor E2020 in rhesus monkeys. Psychopharmacology 1997;131:406-10
   PubMed Web of Science ®Google Scholar
• Marighetto A, Valerio S, Desmedt A, et al. Comparative effects of the alpha7 nicotinic partial agonist, S 24795, and the cholinesterase inhibitor, donepezil, against aging-related deficits in declarative and working memory in mice. Psychopharmacology 2008;197:499-508
   PubMed Web of Science ®Google Scholar
• Van Dam D, Coen K, De Deyn PP. Cognitive evaluation of disease-modifying efficacy of donepezil in the APP23 mouse model for Alzheimer's disease. Psychopharmacology 2008;197:37-43
   PubMed Web of Science ®Google Scholar
• De Bruin N, Pouzet B. Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. Pharmacol Biochem Behav 2006;85:253-60
   PubMed Web of Science ®Google Scholar
• Simon BB, Knuckley B, Powell DA. Galantamine facilitates acquisition of a trace-conditioned eyeblink response in healthy, young rabbits. Learn Mem 2004;11:116-22
   PubMed Web of Science ®Google Scholar
• Winslow JT, Camacho F. Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. Psychopharmacology 1995;121:164-72
   PubMed Web of Science ®Google Scholar
• Gould TJ, Feiro OR. Age-related deficits in the retention of memories for cued fear conditioning are reversed by galantamine treatment. Behav Brain Res 2005;165:160-71
   PubMed Web of Science ®Google Scholar
• O'Neill J, Fitten LJ, Siembieda D, et al. Effects of AF102B and tacrine on delayed match-to-sample in monkeys. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:665-78
   PubMed Web of Science ®Google Scholar
• Dawson GR, Bayley P, Channell S, et al. A comparison of the effects of the novel muscarinic receptor agonist L-689,660 and AF102B in tests of reference and working memory. Psychopharmacology 1994;113:361-8
   PubMed Web of Science ®Google Scholar
• Brandeis R, Dachir S, Sapir M, et al. Reversal of age-related cognitive impairments by an M1 cholinergic agonist, AF102B. Pharmacol Biochem Behav 1990;36:89-95
   PubMed Web of Science ®Google Scholar
• Caccamo A, Oddo S, Billings LM, et al. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006;49:671-82
   PubMed Web of Science ®Google Scholar
• Fischer A, Brandeis R, Chapman S, et al. M1 muscarinic agonist treatment reverse cognitive and cholinergic impairments of apolipoprtein E-deficient mice. J Neurochem 1998;70:1991-7
   PubMed Web of Science ®Google Scholar
• Woodruff-Pak DS. Mecamylamine reversal by nicotine and by a partial alpha7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning. Behav Brain Res 2003;143:159-67
   PubMed Web of Science ®Google Scholar
• Arendash GW, Sengstock GJ, Sanberg PR, et al. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 1995;674:252-9
   PubMed Web of Science ®Google Scholar
• Woodruff-Pak DS, Green JT, Coleman-Valencia C, et al. A nicotinic cholinergic agonist (GTS-21) and eyeblink classical conditioning: acquisition, retention, and relearning in older rabbits. Exp Aging Res 2000;26:323-36
   PubMed Web of Science ®Google Scholar
• Pichat P, Bergis OE, Terranova JP, et al. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007;32:17-34
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ishima T, Fujita Y, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol Psychiatry 2008;63:92-7
   PubMed Web of Science ®Google Scholar
• Beracochea D, Boucard A, Trocme-Thibierge C, et al. Improvement of contextual memory by S 24795 in aged mice: comparison with memantine. Psychopharmacology 2008;196:555-64
   PubMed Web of Science ®Google Scholar
• Sydserff S. AZD0328, an alpha-7 neuronal nicotinic receptor agonist improves novel object recognition for up to 48 hours when administered prior to acquisition at low doses. Soc Neurosci Meeting 2007;906.23
   Google Scholar
• Castner SA, Findlay HA, Smagin G, et al. AZD0328-mediated selective stimulation of alpha7 nicotinic acetylcholine receptors induces immediate and sustained improvements of prefrontal cortical function in nonhuman primates performing working memory tasks. Soc Neurosci Meeting 2007;906.8
   Google Scholar
• Creeley C, Wozniak DF, Labruyere J, et al. Low doses of memantine disrupt memory in adult rats. J Neurosci 2006;26:3923-32
   PubMed Web of Science ®Google Scholar
• Bertoglio LJ, Carobrez AP. Scopolamine given pre-Trial 1 prevents the one-trial tolerance phenomenon in the elevated plus-maze Trial 2. Behav Pharmacol 2004;15:45-54
   PubMed Web of Science ®Google Scholar
• Bresink I, Danysz W, Parsons CG, et al. Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats. J Neural Transm Park Dis Dement Sect 1995;10:11-26
   PubMedGoogle Scholar
• Pieta Dias C, Martins de Lima MN, Presti-Torres J, et al. Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 2007;146:1719-25
   PubMed Web of Science ®Google Scholar
• Minkeviciene R, Banerjee P, Tanila H. Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2004;311:677-82
   PubMed Web of Science ®Google Scholar
• Hampson RE, Rogers G, Lynch G, et al. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 1998;18:2740-47
   PubMed Web of Science ®Google Scholar
• Davis CM, Moskovitz B, Nguyen MA, et al. A profile of the behavioral changes produced by facilitation of AMPA-type glutamate receptors. Psychopharmacology 1997;133:161-7
   PubMed Web of Science ®Google Scholar
• Rutten K, Prickaerts J, Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 2006;85:132-8
   PubMed Web of Science ®Google Scholar
• Monti B, Berteotti C, Contestabile A. Subchronic rolipram delivery activates hippocampal CREB and arc, enhances retention and slows down extinction of conditioned fear. Neuropsychopharmacology 2006;31:278-86
   PubMed Web of Science ®Google Scholar
• Rutten K, Lieben C, Smits L, et al. The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology 2007;192:275-82
   PubMed Web of Science ®Google Scholar
• Zhang HT, O'Donnell JM. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology 2000;150:311-6
   PubMed Web of Science ®Google Scholar
• Egawa T, Mishima K, Matsumoto Y, et al. Rolipram and its optical isomers, phosphodiesterase 4 inhibitors, attenuated the scopolamine-induced impairments of learning and memory in rats. Jpn J Pharmacol 1997;75:275-81
   PubMedGoogle Scholar
• Zhang HT, Crissman AM, Dorairaj NR, et al. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology 2000;23:198-204
   PubMed Web of Science ®Google Scholar
• Ramos BP, Birnbaum SG, Lindenmayer I, et al. Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron 2003;40:835-45
   PubMed Web of Science ®Google Scholar
• Bourtchouladze R, Lidge R, Catapano R, et al. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA 2003;100:10518-22
   PubMed Web of Science ®Google Scholar
• Prickaerts J, Steinbusch HWM, Smits JFM, et al. Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast. Eur J Pharmacol 1997;337:125-36
   PubMed Web of Science ®Google Scholar
• Campbell E, Edwards T. Zaprinast consolidates long-term memory when administered to neonate chicks trained using a weakly reinforced single trial passive avoidance task. Behav Brain Res 2006;169:181-5
   PubMed Web of Science ®Google Scholar
• Prickaerts J, van Staveren WC, Sik A, et al. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002;113:351-61
   PubMed Web of Science ®Google Scholar
• Baratti CM, Boccia MM. Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav Pharmacol 1999;10:731-7
   PubMed Web of Science ®Google Scholar
• Devan BD, Sierra-Mercado D Jr, Jimenez M, et al. Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol Biochem Behav 2004;79:691-9
   PubMed Web of Science ®Google Scholar
• Devan BD, Bowker JL, Duffy KB, et al. Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology 2006;183:439-45
   PubMed Web of Science ®Google Scholar